1. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; March 2007-September 2007
2. A Multi-center, 10-Week, Randomized, Double-blind Study of Sertraline and Placebo in Children and Adolescents with Post-traumatic Stress Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer Pharmaceuticals Group; January 2003 – September 2007
3. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.
4. A Multi-center, Randomized, Double-blind, Placebo-controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients Aged 10–17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.
5. A Multi-center, Open-label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.
6. A Double-blind Multi-center Study Comparing The Safety and Efficacy of Ziprasidone to Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000 – August 2000
7. A Double-blind, 12-Month Continuation Protocol for Patients who Successfully Completed Protocol RO548. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000 – August 2001
8. Olanzapine Plus Fluoxetine Combination Therapy in Treatment Resistant Depression: A Dosing Range Study: Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.: Sponsor: Eli Lilly and Co.; March 2000 – July 2002
9. A Multi-center, Randomized, Double-blind Study of Flexible Doses of Aripriprazole vs. Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; August 2000 – July 2002
10. A Multi-center, Randomized, Double-blind Study and Tolerability Study of Flexible Doses of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; October 2000 – July 2002
11. The Efficacy and Safety of Risperidone in the treatment of children and adolescents with schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D.; Sponsor: Janssen/Medex; April 2001 – July 2002
12. Olanzapine vs. Risperidone in the treatment of Bipolar I disorder, mixed or manic. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – July 2002
13. Olanzapine vs. Ziprasidone in the treatment of Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – July 2002
14. A comparison of fasting triglyceride levels cohorts with schizophrenic and related disorder treated chronically with Olanzapine, Risperidone and typical anti-psychotics. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – April 2002
15. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.
16. A Phase III, Open-label Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.
17. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of ADDERALL XR® with an Open-label Extension, in the Treatment of Adolescents Aged 13–17 with Attention Deficit Hyperactivity Disorder (ADHD). Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.
18. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company
19. Olanzapine vs. Placebo in the Treatment of Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company
20. The Study of Olanzapine plus Fluoxetine in Combination for Treatment-resistant Depression Without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company
21. Population Pharmacokinetic Study in Adolescent Patients with Schizophrenia or Bipolar I Disorder Treated with Olanzapine. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company
©2006
Jeanette E. Cueva and David Sert Krakow. All rights reserved.
